TransMedics Total Stockholder Equity vs Long Term Debt Analysis

TMDX Stock  USD 86.71  0.40  0.46%   
TransMedics financial indicator trend analysis is much more than just breaking down TransMedics Group prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether TransMedics Group is a good investment. Please check the relationship between TransMedics Total Stockholder Equity and its Long Term Debt accounts. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TransMedics Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.

Total Stockholder Equity vs Long Term Debt

Total Stockholder Equity vs Long Term Debt Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of TransMedics Group Total Stockholder Equity account and Long Term Debt. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between TransMedics' Total Stockholder Equity and Long Term Debt is 0.59. Overlapping area represents the amount of variation of Total Stockholder Equity that can explain the historical movement of Long Term Debt in the same time period over historical financial statements of TransMedics Group, assuming nothing else is changed. The correlation between historical values of TransMedics' Total Stockholder Equity and Long Term Debt is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Total Stockholder Equity of TransMedics Group are associated (or correlated) with its Long Term Debt. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Long Term Debt has no effect on the direction of Total Stockholder Equity i.e., TransMedics' Total Stockholder Equity and Long Term Debt go up and down completely randomly.

Correlation Coefficient

0.59
Relationship DirectionPositive 
Relationship StrengthWeak

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Long Term Debt

Long-term debt is a debt that TransMedics Group has held for over one year. Long-term debt appears on TransMedics Group balance sheet and also includes long-term leases. The most common forms of long term debt are bonds payable, long-term notes payable, mortgage payable, pension liabilities, and lease liabilities. In the corporate world, long-term debt is generally used to fund big-ticket items, such as machinery, buildings, and land. The total of long-term debt reported on TransMedics Group balance sheet is the sum of the balances of all categories of long-term debt. Debt that is not due within the current year and is often considered to be financing activities that are to be repaid over several years.
Most indicators from TransMedics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into TransMedics Group current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in TransMedics Group. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment.
At this time, TransMedics' Selling General Administrative is fairly stable compared to the past year. Sales General And Administrative To Revenue is likely to rise to 0.96 in 2024, despite the fact that Tax Provision is likely to grow to (1.4 M).
 2021 2022 2023 2024 (projected)
Total Operating Expenses60.6M96.7M182.8M192.0M
Research Development22.3M26.8M36.1M22.2M

TransMedics fundamental ratios Correlations

0.980.7-0.090.81-0.750.860.99-0.120.98-0.370.990.941.00.610.910.960.990.72-0.090.980.980.960.640.98-0.09
0.980.7-0.160.8-0.80.920.96-0.060.97-0.370.990.950.980.640.930.980.980.73-0.040.970.970.940.650.97-0.03
0.70.7-0.120.93-0.740.470.690.060.59-0.080.730.530.730.960.830.820.70.87-0.240.60.580.520.160.580.01
-0.09-0.16-0.120.00.12-0.36-0.08-0.44-0.170.17-0.14-0.2-0.07-0.090.01-0.15-0.110.240.35-0.16-0.13-0.14-0.34-0.14-0.35
0.810.80.930.0-0.750.580.79-0.270.71-0.050.820.660.850.860.890.870.810.84-0.20.720.710.650.270.71-0.3
-0.75-0.8-0.740.12-0.75-0.69-0.720.01-0.660.01-0.81-0.66-0.78-0.79-0.82-0.82-0.73-0.790.01-0.66-0.65-0.6-0.27-0.650.02
0.860.920.47-0.360.58-0.690.82-0.020.9-0.320.880.870.840.440.750.840.850.48-0.150.90.890.880.750.890.02
0.990.960.69-0.080.79-0.720.82-0.080.96-0.50.980.930.980.590.930.941.00.71-0.070.960.960.940.560.96-0.04
-0.12-0.060.06-0.44-0.270.01-0.02-0.08-0.05-0.31-0.06-0.07-0.140.1-0.1-0.02-0.080.0-0.04-0.05-0.08-0.040.06-0.070.98
0.980.970.59-0.170.71-0.660.90.96-0.05-0.420.970.970.960.490.830.920.970.62-0.071.01.01.00.771.0-0.01
-0.37-0.37-0.080.17-0.050.01-0.32-0.5-0.31-0.42-0.36-0.46-0.340.02-0.39-0.32-0.45-0.12-0.16-0.42-0.44-0.44-0.14-0.44-0.43
0.990.990.73-0.140.82-0.810.880.98-0.060.97-0.360.950.990.660.930.980.980.75-0.050.970.970.940.620.97-0.03
0.940.950.53-0.20.66-0.660.870.93-0.070.97-0.460.950.920.450.810.910.940.590.120.970.970.970.740.97-0.03
1.00.980.73-0.070.85-0.780.840.98-0.140.96-0.340.990.920.650.930.960.990.75-0.10.960.960.930.590.96-0.12
0.610.640.96-0.090.86-0.790.440.590.10.490.020.660.450.650.770.760.60.9-0.180.50.480.420.080.480.05
0.910.930.830.010.89-0.820.750.93-0.10.83-0.390.930.810.930.770.950.920.870.010.840.850.790.330.84-0.06
0.960.980.82-0.150.87-0.820.840.94-0.020.92-0.320.980.910.960.760.950.950.830.00.930.920.890.570.920.0
0.990.980.7-0.110.81-0.730.851.0-0.080.97-0.450.980.940.990.60.920.950.71-0.10.980.980.950.610.97-0.05
0.720.730.870.240.84-0.790.480.710.00.62-0.120.750.590.750.90.870.830.710.090.630.620.570.150.620.02
-0.09-0.04-0.240.35-0.20.01-0.15-0.07-0.04-0.07-0.16-0.050.12-0.1-0.180.010.0-0.10.09-0.07-0.05-0.04-0.09-0.050.05
0.980.970.6-0.160.72-0.660.90.96-0.051.0-0.420.970.970.960.50.840.930.980.63-0.071.00.990.761.0-0.01
0.980.970.58-0.130.71-0.650.890.96-0.081.0-0.440.970.970.960.480.850.920.980.62-0.051.00.990.751.0-0.03
0.960.940.52-0.140.65-0.60.880.94-0.041.0-0.440.940.970.930.420.790.890.950.57-0.040.990.990.81.00.01
0.640.650.16-0.340.27-0.270.750.560.060.77-0.140.620.740.590.080.330.570.610.15-0.090.760.750.80.760.06
0.980.970.58-0.140.71-0.650.890.96-0.071.0-0.440.970.970.960.480.840.920.970.62-0.051.01.01.00.76-0.02
-0.09-0.030.01-0.35-0.30.020.02-0.040.98-0.01-0.43-0.03-0.03-0.120.05-0.060.0-0.050.020.05-0.01-0.030.010.06-0.02
Click cells to compare fundamentals

TransMedics Account Relationship Matchups

TransMedics fundamental ratios Accounts

201920202021202220232024 (projected)
Total Assets105.3M152.0M134.9M277.1M706.0M741.3M
Total Current Liabilities16.1M11.9M23.2M23.7M54.9M57.7M
Total Stockholder Equity54.6M103.9M67.9M187.4M137.2M144.1M
Other Liab1.1M759K389K1.6M1.4M901.6K
Net Tangible Assets54.6M103.9M67.9M187.4M215.5M226.3M
Retained Earnings(369.5M)(398.2M)(442.4M)(478.7M)(503.7M)(528.9M)
Accounts Payable7.2M1.2M6.7M3.3M12.7M13.4M
Cash20.1M24.6M25.6M201.2M394.8M414.6M
Long Term Debt34.1M34.7M35.2M58.7M506.2M531.5M
Inventory11.2M11.9M14.9M20.6M44.2M46.4M
Total Liab50.7M48.1M67.0M89.8M568.8M597.3M
Total Current Assets100.0M146.8M118.7M252.3M510.7M536.2M
Common Stock424.1M502.2M510.5M666.3M641.1M375.9M
Property Plant Equipment4.8M4.8M15.7M24.4M28.0M29.4M
Other Current Liab8.7M10.4M16.3M17.2M36.2M38.0M
Net Receivables6.6M6.9M5.9M27.6M63.6M66.8M
Common Stock Shares Outstanding14.2M24.7M27.6M29.6M32.5M24.3M
Other Stockholder Equity(105.3M)(95K)68.0M(225K)(202.5K)(192.4K)
Short Long Term Debt Total34.1M34.7M43.8M67.6M515.9M541.7M
Property Plant And Equipment Net4.8M4.8M15.7M24.4M180.5M189.5M
Current Deferred Revenue166K263K250K241K2.0M2.1M
Net Debt14.1M10.1M(17.0M)(133.6M)121.1M127.2M
Non Current Assets Total5.3M5.3M16.2M24.9M195.4M205.2M
Cash And Short Term Investments80.7M125.6M92.5M201.2M394.8M414.6M
Common Stock Total Equity331.2M424.1M502.2M510.5M587.1M389.0M
Long Term Debt Total33.7M34.1M34.7M35.2M40.5M31.8M
Liabilities And Stockholders Equity105.3M152.0M134.9M277.1M706.0M741.3M
Non Current Liabilities Total34.5M36.3M43.8M66.1M513.9M539.6M
Other Current Assets1.5M4.7M5.5M2.9M8.0M8.4M
Net Invested Capital88.8M138.5M103.1M246.1M643.4M675.6M
Property Plant And Equipment Gross4.8M4.8M15.7M24.4M201.8M211.9M
Accumulated Other Comprehensive Income(2K)(95K)(188K)(225K)(199K)(209.0K)
Net Working Capital83.9M134.9M95.5M228.6M455.7M478.5M
Capital Stock424.1M502.2M510.5M666.3M641.1M563.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for TransMedics Stock Analysis

When running TransMedics' price analysis, check to measure TransMedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TransMedics is operating at the current time. Most of TransMedics' value examination focuses on studying past and present price action to predict the probability of TransMedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TransMedics' price. Additionally, you may evaluate how the addition of TransMedics to your portfolios can decrease your overall portfolio volatility.